GlassScriptPhysician profile
Mitchell S Karl
NPI 1932291614
$7,402.96
in general payments reported to CMS, 2019-2025
30 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,042 · 2020: $2,092 · 2021: $267 · 2022: $436 · 2023: $335 · 2024: $1,145 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036 · Travel and Lodging: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,036.33 |
| Travel and Lodging | $529.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $2,742.11 | 2019-2020 | |
| Cvrx, INC. | $701.74 | 2021-2024 | Barostim Neo System |
| Atricure, INC. | $612.36 | 2022-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Amgen INC. | $590.89 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $338.28 | 2025 | |
| Sanofi-Aventis U.S. LLC | $335.42 | 2019-2024 | |
| Pfizer INC. | $324.61 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $280.85 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $263.96 | 2019-2023 | Wainua |
| Novo Nordisk INC | $231.25 | 2022-2025 | Ozempic, Rybelsus |
| Cleerly, INC. | $185.16 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
| Medtronic Vascular, INC. | $160.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $136.22 | 2021-2025 | |
| Lilly USA, LLC | $88.71 | 2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $47.59 | 2022-2024 | Watchman Flx |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $43.39 | 2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $43.26 | 2025 | |
| Janssen Pharmaceuticals, INC | $42.19 | 2020 | |
| Abbott Laboratories | $39.38 | 2024 | Aveir |
| La Jolla Pharmaceutical Company | $22.76 | 2019 | |
| Glaxosmithkline, LLC. | $22.63 | 2025 | Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $21.80 | 2023 | Quviviq |
| Eisai INC. | $20.92 | 2025 | |
| Astellas Pharma US INC | $20.59 | 2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $20.51 | 2019 | |
| Bridgebio Pharma, INC. | $19.89 | 2025 | Attruby |
| Biohaven Pharmaceutical Holding Company LTD. | $18.79 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.03 | 2021 | |
| Merck Sharp & Dohme LLC | $13.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Karl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.